All In Biotech

Drug Trial Radar · NCT04536337

A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, First-in-Human Study of Orally Administered ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single-Ascending Doses (Part 1) and Multiple-Ascending Doses in Healthy Volunteers (Part 2), and Multiple Doses in Subjects With Chronic Hepatitis B (Part 3)

Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 165 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

165

Actual

Start

Oct 22, 2020

Primary completion

Jun 16, 2025

Study completion Jun 16, 2025

Sponsor

Lead sponsor
Aligos TherapeuticsIndustry
Sponsor type
Industry
First posted
Sep 2, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if ALG-000184 is safe, well-tolerated, and works to treat chronic hepatitis B virus (HBV) infection. The main questions it aims to answer are: Is ALG-000184 safe and well-tolerated when given alone or with entecavir (a standard HBV treatment)? Does ALG-000184 reduce HBV viral levels in the blood of patients with chronic hepatitis B? How does the body process ALG-000184 (pharmacokinetics)? Researchers will compare ALG-000184 to placebo (a look-alike substance that contains no drug) to see if ALG-000184 works better at reducing hepatitis B viral markers. The study has five parts: Parts 1 and 2: Healthy volunteers will receive single or multiple doses of ALG-000184 or placebo Part 3: Patients with chronic hepatitis B will receive ALG-000184 or placebo daily for 28 days Part 4: Patients with chronic hepatitis B will receive ALG-000184 or placebo combined with entecavir for 12 weeks (may be extended up to 96 weeks) Part 5: Additional groups of patients with chronic hepatitis B will receive ALG-000184 with entecavir for 12 weeks (may be extended up to 96 weeks) Participants will: Take study medication orally as directed Visit the clinic regularly for blood tests, physical examinations, and other safety assessments Have their HBV viral markers measured to determine if the treatment is working

Conditions

  • Chronic Hepatitis B

Interventions

  • ALG-000184Drug

    Single or multiple doses of ALG-000184

  • PlaceboDrug

    Single or multiple doses of Placebo

  • EntecavirDrug

    multiple doses of Entecavir

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: up to 8 days for Part 1
  2. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: up to 21 days for Part 2
  3. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: up to 112 days for Part 3
  4. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Up to 756 days for parts 4 & 5

Locations

10 sites in 6 countries. Site status is shown where the registry gives one.

  • Saint Vincent's Hospital Melbourne

    Fitzroy, Victoria, Australia

  • Western Health

    Footscray, Victoria, Australia

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • Prince of Wales

    Shatin, Hong Kong

  • CAP Research

    Quatre Bornes, Mauritius, Mauritius

  • PMSI Republican Clinical Hospital "T. Mosneaga", ARENSIA Exploratory Medicine Phase I Unit

    Chisinau, Moldova

  • ACS

    Auckland, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.